More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$12.62B
EPS
0.56
P/E ratio
23.1
Price to sales
2.29
Dividend yield
3.28%
Beta
0.550987
Previous close
$30.08
Today's open
$29.91
Day's range
$29.37 - $29.94
52 week range
$28.80 - $38.79
show more
CEO
Deepak Nath
Employees
17349
Headquarters
Watford,
Exchange
New York Stock Exchange
Shares outstanding
424862010
Issue type
American Depository Receipt
Healthcare
Medical Equipment & Supplies
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript
Smith & Nephew plc (SNN) Shareholder/Analyst Call Transcript
Seeking Alpha • Jun 11, 2026

Smith & Nephew's robotics push wins surgeon backing
Smith & Nephew PLC (LSE:SN) efforts to expand its surgical robotics platform and strengthen its orthopaedics pipeline received a vote of confidence from surgeons at a recent investor event, according to analysts at JPMorgan. Analyst Veronika Dubajova said discussions at the medical technology group's Expert Surgeon Insights event in London left her incrementally more positive on the prospects for CORI, Smith & Nephew's robotic-assisted surgery platform.
Proactive Investors • Jun 10, 2026

Smith+Nephew announces first clinical cases with the next generation CORI◊XT Handheld Robotics Platform across knee and shoulder arthroplasty
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology company, announces the completion of the first clinical cases performed using the next‑generation CORI◊ XT Handheld Robotics Platform, marking an important milestone in the clinical introduction of its latest handheld robotics technology. CORI XT Handheld Robotic Platform is designed to be the single handheld robotics platform for all orthopaedic needs - partial to revision knee, hip*, and anatomic and reverse shoulders - with a footprint tailored to the unique needs of hospitals and ambulatory surgical suites settings.
GlobeNewsWire • Jun 8, 2026

Smith+Nephew launch next generation LEAF™ Patient Monitoring System – an innovative pressure injury prevention platform delivering proven clinical impact
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the US launch of next generation LEAF ♢ Patient Monitoring System, a data-driven pressure injury prevention platform designed to help health care providers tackle the growing burden of hospital-acquired pressure injuries (HAPIs) by strengthening protocols and outcomes. The LEAF System uses a wearable sensor to monitor patient mobility and provide real-time turn status updates, helping to improve workflow efficiency, turn quality, and protocol adherence.1-3
GlobeNewsWire • Jun 1, 2026

VEEV Boosts MedTech Quality Management With Smith+Nephew Partnership
Veeva Systems expands its medtech reach as Smith+Nephew adopts Veeva Quality Cloud to modernize global quality operations and training.
Zacks Investment Research • May 13, 2026

UK's Smith+Nephew keeps annual outlook, plans share buyback as quarterly revenue rises
Medical products maker Smith+Nephew posted a 3.1% rise in first-quarter underlying revenue on Wednesday, helped by strong sports medicine and wound management performance, and kept its annual outlook unchanged while announcing a $500 million share buyback.
Reuters • May 6, 2026

Smith & Nephew plc (SNN) Q1 2026 Sales/Trading Call Transcript
Smith & Nephew plc (SNN) Q1 2026 Sales/Trading Call Transcript
Seeking Alpha • May 6, 2026

Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound Management Association (EWMA) Conference, Bremen between 6-8 May 2026.
GlobeNewsWire • May 5, 2026

SNN vs. BSX: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Zacks Investment Research • May 5, 2026

SNN's CARTIHEAL Cartilage Implant Beats Standard Care in 5-Year Study
Smith+Nephew's CARTIHEAL implant shows superior 5-year outcomes vs. standard care, with a new CPT code set to boost adoption and expand cartilage repair reach.
Zacks Investment Research • Apr 24, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Smith & Nephew SNATS Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.